FLT3 and acute myeloid leukemia: Interestingly, in the context of cell proliferation, clonogenicity, and drug-induced cell death, there was no much difference between two human BMC harboring KMT2A-PTD/DNMT3A-MT with FLT3-ITD (AML#5) or without FLT3-ITD (AML#6).